Rare disease and real-world data: How RWD can help deliver better therapies and better outcomes
Planning a clinical trial for uncommon diseases is challenging due to small patient populations and knowledge gaps, which has a detrimental impact on the patient experience. In order to make more informed decisions and find new treatments for rare diseases, real-world data could be used to provide reliable proof and easier access to markets.

You’ll learn how the following industry leaders deliver patient-centric value:
Read this report and you’ll understand:

  • The opportunities that RWD can bring in improving rare disease knowledge and treatments
  • Best practice to develop your own use of RWD to facilitate rare disease therapy solutions
  • How the industry is developing external partnerships to build the capabilities they need
  • What regulators expect from pharma and how regulatory pathways factor in
  • Outlining the best model approach for RWD 
Access this report now – fill in your details on the right and learn how RWD can help deliver improved patient-outcomes ->
Please let me know if you have any feedback.

Kind regards,
Charlotte Bastiaanse
Conference Producer
Reuters Events
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.

Download this 11-page report on insight generation in Market Access and RWE
Learn from medical leaders in Pfizer, Alexion, Johnson & Johnson, Cegedim, Icon and more!
Reuters Events will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy: https://www.thomsonreuters.com/en/privacy-statement.html.